[CAS NO. 14892-97-8] SCR7
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [14892-97-8]
Store
Catalog
SLK-S7742
Brand
Selleck
CAS
14892-97-8
DESCRIPTION [14892-97-8]
Overview
| MDL | MFCD02167478 |
|---|---|
| Molecular Weight | 332.38 |
| Molecular Formula | C18H12N4OS |
| SMILES | O=C1NC(NC2=NC(C3=CC=CC=C3)=C(C4=CC=CC=C4)N=C12)=S |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0086 mL | 15.0430 mL | 30.0860 mL |
| 5 mM | 0.6017 mL | 3.0086 mL | 6.0172 mL |
| 10 mM | 0.3009 mL | 1.5043 mL | 3.0086 mL |
| 50 mM | 0.0602 mL | 0.3009 mL | 0.6017 mL |
Description
SCR7 is a specific inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using in mammalian cells and mouse embryos.
Targets
| DNA Ligase IV [1] |
In vitro
SCR7 effectively inhibits the formation of multimers at 200 μM and above. SCR7 successfully inhibits cell proliferation of MCF7, A549, HeLa, T47D, A2780, HT1080, and Nalm6 with IC50 of 40, 34, 44, 8.5, 120, 10, and 50 μM, respectively. SCR7 suppresses the NHEJ repair of CRISPR-Cas9-induced DSBs.SCR7 increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
In vivo
SCR7 treatment (10 mg/kg, i.m.) significantly reduces breast adenocarcinoma-induced tumor, and exhibits 4-fold increase in lifespan compared with control group. However, in Swiss albino mice with Dalton’s lymphoma tumor model, SCR7 (20 mg/kg, i.p.) exhibits neither tumor regression nor increase in lifespan. In BALB/c mice, SCR7 (20 mg/kg, i.p.) significantly enhances the cytotoxic effects of radiation, etoposide and 3-Aminobenzamide on tumor derived from Dalton’s lymphoma (DLA) cells.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.